• Above all, we make a difference.
  • Diagnosis References

    1. American Cancer Society. Benign breast conditions: not all lumps are cancer. http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/forwomenfacingabreastbiopsy/breast-biopsy-benign-breast-conditions, 2015.
    2. Wood WC, Muss HB, Solin LJ, Olopade OI. Chapter 33, Section 2: Malignant tumors of the breast. In Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principals and Practice of Oncology, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2005.
    3. Sung JS and Comstock CE. Chapter 15: Image-guided biopsy of nonpalpable breast lesions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    4. Brancato B, Crocetti E, Bianchi S, et al. Accuracy of needle biopsy of breast lesions visible on ultrasound: audit of fine needle versus core needle biopsy in 3233 consecutive samplings with ascertained outcomes. Breast. 21(4):449-54, 2012.
    5. Rouse HC, Ussher S, Kavanagh AM, Cawson JN. Examining the sensitivity of ultrasound-guided large core biopsy for invasive breast carcinoma in a population screening programme. J Med Imaging Radiat Oncol. 57(4):435-43, 2013.
    6. Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 190(1):202-7, 2008.
    7. Florentine BD, Staymates B, Rabadi M, Barstis J, Black A for the Cancer Committee of the Henry Mayo Newhall Memorial Hospital. The reliability of fine-needle aspiration biopsy as the initial diagnostic procedure for palpable masses: a 4-year experience of 730 patients from a community hospital-based outpatient aspiration biopsy clinic. Cancer. 107(2):406-16, 2006.
    8. Bleicher RJ. Chapter 4: Management of the palpable breast mass, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    9. Moffat FL. Chapter 28: Clinical and pathologic prognostic and predictive factors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    10. Chung AP, Giuliano AE. Chapter 37: Sentinel lymph node biopsy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    11. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 349:546-53, 2003.
    12. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Cancer. 106(1):4-16, 2006.
    13. Lyman GH, Temin S, Edge SB, et al. for the American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 32(13):1365-83, 2014.
    14. Dillon D, Guidi AJ, Schnitt SJ. Chapter 25: Pathology of Invasive Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    15. Overmoyer B, Pierce LJ. Chapter 59: Inflammatory Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    16. National Cancer Institute. Inflammatory breast cancer. http://www.cancer.gov/types/breast/ibc-fact-sheet, 2016.
    17. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 55(5):1200-8, 2003.
    18. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 97(13):966-75, 2005.
    19. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
    20. Yang R, Cheung MC, Hurley J, et al. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat. 117(3):631-41, 2009.
    21. Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 29(8):1014-21, 2011.
    22. Matro JM, Li T, Cristofanilli M, et al. Inflammatory breast cancer management in the National Comprehensive Cancer Network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. S1526-8209(14)00112-8, 2014.
    23. Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 38(3):242-7, 2015.
    24. Schairer C, Li Y, Frawley P, et al. Risk factors for inflammatory breast cancer and other invasive breast cancers. J Natl Cancer Inst. 105(18):1373-84, 2013.
    25. Hansen NM. Chapter 63: Paget’s Disease, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    26. National Cancer Institute. Paget Disease of the Breast. http://www.cancer.gov/types/breast/paget-breast-fact-sheet, 2012.
    27. Terando AM, Agnese DM, Holmes DR. Treatment and prognosis of rare breast cancers. Ann Surg Oncol. 22(10):3225-9, 2015.
    28. Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 65(5):441-6, 2012.
    29. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR. Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 95(35):e4614, 2016.
    30. American Cancer Society. Hormone therapy for breast cancer. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-hormone-therapy, 2016.
    31. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 122(5):1089-94, 2008.
    32. Esserman LJ and Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer, in Up-to-Date (Burstein H, Vora SR, eds.). Up-to-Date, 2016.
    33. American Cancer Society. Targeted therapy for breast cancer. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-targeted-therapy, 2016.
    34. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 30;351(27):2817-26, 2004.
    35. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 28(11):1829-34, 2010.
    36. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 373(21):2005-14, 2015.
    37. Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 105(10):701-10, 2013.
    38. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10(4):R67, 2008.
    39. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 104(1):120-7, 2011.
    40. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 355(6):560-9, 2006.
    41. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 28(10):1684-91, 2010.
    42. Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. In: UpToDate. Hayes DF, Vora SR (eds.). Waltham, MA: UpToDate, 2016.
    43. Carey LA, Cheang MCU, Perou CM. Chapter 29: Genomics, Prognosis, and Therapeutic Interventions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
    44. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 106(5), 2014.
    45. Koboldt DC, Fulton RS, McLellan MD, et al. for the Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490(7418):61-70, 2012.
    46. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 29(29):3885-91, 2011.
    47. Metzger-Filho O, Sun Z, Viale G, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 31(25):3083-90, 2013.
    48. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer. 116(11):2549-59, 2010.
    49. Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 21(10):1848-55, 2012.
    50. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 107(6), 2015.
    51. Sineshaw HM, Gaudet M, Ward EM, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat. 145(3):753-63, 2014.
    52. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 26(26):4282-8, 2008.
    53. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 118(11):2787-95, 2012.
    54. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 33(4):304-11, 2015.
    55. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 27(28):4701-8, 2009.
    56. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 121(1):8-16, 2015.
    57. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 103(3):250-63, 2011.
    58. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer. 116(21):4933-43, 2010.
    59. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 137(2):579-87, 2013.
    60. Hines LM, Risendal B, Slattery ML, et al. Comparative analysis of breast cancer risk factors among Hispanic and non-Hispanic white women. Cancer. 116(13):3215-23, 2010.
    61. Palmer JR, Viscidi E, Troester MA, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. 106(10), 2014.
    62. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 117(16):3658-69, 2011.
    63. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 103(6):470-7, 2011.
    64. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 131(1):159-67, 2012.
    65. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
    66. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 137(1):307-14, 2013.
    67. Menezes GL, Knuttel FM, Stehouwer BL, Pijnappel RM, van den Bosch MA. Magnetic resonance imaging in breast cancer: A literature review and future perspectives. World J Clin Oncol. 5(2):61-70, 2014.
    68. Harnan SE, Cooper KL, Meng Y, et al. Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 37(11):928-36, 2011.
    69. Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg. 216(5):966-75, 2013.
    70. Houssami N, Turner R, Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg. 257(2):249-55, 2013.
    71. Arnaout A, Catley C, Booth CM, et al. Use of preoperative magnetic resonance imaging for breast cancer: a Canadian population-based study. JAMA Oncol. 1(9):1238-50, 201574-75.
    72. Killelea BK, Long JB, Chagpar AB, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treat. 141(1):155-63, 2013.
    73. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 32(5):392-401, 2014.
    74. Förnvik D, Zackrisson S, Ljungberg O, et al. Breast tomosynthesis: Accuracy of tumor measurement compared with digital mammography and ultrasonography. Acta Radiol. 51(3):240-7, 2010.
    75. Helvie MA. Digital mammography imaging: breast tomosynthesis and advanced applications. Radiol Clin North Am. 48(5):917-29, 2010.
    76. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. Radiology. 266(1):104-13, 2013.
    77. Almubarak M, Osman S, Marano G, Abraham J. Role of positron-emission tomography scan in the diagnosis and management of breast cancer. Oncology (Williston Park). 23(3):255-61, 2009.
    78. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 34(10):1134-50, 2016.
    79. Cardoso F, van't Veer LJ, Bogaerts J, et al. for the MINDACT Investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 375(8):717-29, 2016.
    80. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
    81. Dawood S, Broglio K, Valero V, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 113(9):2422-30, 2008.
    82. De Giorgi U, Valero V, Rohren E , et al. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 27(20):3303-11, 2009.
    83. Pierga JY, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 23(3):618-24, 2012.
    84. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368(13):1199-209, 2013.
    85. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 26(8):1208-15, 2008.
    86. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 27(13):2177-84. 2009.
    87. Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol. 132(2):237-45, 2009.
    88. Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 116(14):3330-7, 2010.
    89. Rack B, Schindlbeck C, Jückstock J, et al. for the SUCCESS Study Group. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 106(5), 2014.
    90. Hall CS, Karhade MG, Bowman Bauldry JB, et al. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J Am Coll Surg. 223(1):20-9, 2016.
    91. National Cancer Institute. Stage information for breast cancer. http://www.cancer.gov/types/breast/hp/breast-treatment-pdq#section/_27, 2016.
    92. Weaver DL, Ashikaga T, Krag DN, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 364(5):412-21, 2011.
    93. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 306(4):385-93, 2011.
    94. Massimino KP, Hessman CJ, Ellis MC, Naik AM, Vetto JT. Impact of American College of Surgeons Oncology Group Z0011 and National Surgical Adjuvant Breast and Bowel Project B-32 trial results on surgeon practice in the Pacific Northwest. Am J Surg. 203(5):618-22, 2012.
    95. Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with Oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 31(22):2783-90, 2013.
    96. Caan BJ, Sweeney C, Habel LA, et al. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 23(5):725-34, 2014.
    97. Sestak I, Cuzick J, Dowsett M, et al. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J Clin Oncol. 33(8):916-22, 2015.
    98. Chen L, Li CI, Tang MT, et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. 25(9):1297-304, 2016.
    99. Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph Node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 264(3):413-20, 2016.
    100. Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 35(24):2838-2847, 2017. 
    101. Harris L, Fritsche H, Mennel R, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25(33):5287-312, 2007.
    102. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 32(31):3483-9, 2014.
    103. Hayes DF. Systemic treatment for metastatic breast cancer: general principles, in Up-to-Date (Burstein H, Vora SR, eds.). Up-to-Date, 2016.

    Updated 08/30/17


    Diagnosis Home




Tools & Resources


Related Video



1-877 GO KOMEN